Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
Author: Mellor, J.
Brown, M.
Irving, H.
Zalcberg, J.
Dobrovic, A.
Citation: Journal of Hematology & Oncology, 2013; 6(1):1-10
Publisher: BioMed Central
Issue Date: 2013
ISSN: 1756-8722
Statement of
James D Mellor, Michael P Brown, Helen R Irving, John R Zalcberg and Alexander Dobrovic
Abstract: Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.
Keywords: FCGR2A; FCGR3A; trastuzumab; rituximab; cetuximab; ADCC
Rights: © 2013 Mellor et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
RMID: 0020137816
DOI: 10.1186/1756-8722-6-1
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_85793.pdfPublished version330.22 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.